US stock · figures in US dollars · scored on full-year results
IQVIA IQVIA Holdings, Inc. Common Stock
IQVIA scores 42/100 on fundamentals: in the bottom 17% of 503 scored S&P 500 stocks. Its strongest area is Cash & Dividends (75/100); its weakest is Price Fairness (0/100). It carries 2 warning flags: Weak Spot, Limited Data.
- Carries a Weak Spot flag
- Carries a Limited Data flag
A financially stretched, expensively priced stock, but price fairness needs attention.
Nearby peers
Ranks #48 of 60 in Healthcare by score
One-Minute Summary
Why IQVIA scores 42
A financially stretched, expensively priced stock, but price fairness needs attention.
Business Strength
63Why 63?
No data: Quarterly Momentum
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 15.5% over 4 years: customers keep spending more with this company.
Profit has moved sideways: stable, but not compounding your money faster each year.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 8.7% over the last 5 quarters: customers keep spending more with this company.
Profit has moved sideways over the last 5 quarters.
Financial Safety
17Why 17?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings grew about 17.4% over 4 years: watch this; rising debt adds pressure in bad times.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
75Why 75?
Show 3 charts
Operating vs Free Cash Flow
The business generates real cash, and more of it each year: a very healthy sign.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
0Why 0?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 23.5% over the past year.
Risk
63Why 63?
No data: Inventory vs Sales (4yr) · Quarterly Consistency
Sector peers
IQVIA (IQV) scores 42/100 (Okay) on Score Your Stock's educational fundamentals model: in the bottom 17% of 503 scored S&P 500 stocks.
Its strongest pillar is Cash & Dividends (75/100); its weakest is Price Fairness (0/100).
IQVIA ranks #48 of 60 scored Healthcare stocks on Score Your Stock.
IQVIA (IQV) has not paid a dividend in the last 12 months.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy IQV. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
IQVIA (IQV) is a Healthcare company (Diagnostics & Research). On Score Your Stock's fundamentals check, it scores 42/100, rated Okay. Its biggest strength is Cash & Dividends (75/100); its main watch-out is Price Fairness (0/100). Shares currently cost about 32 years of its current profit to buy (P/E 31.6×). Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/iqv-iqvia
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Div yield | P/E Ratio | P/B Ratio | PEG Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 17.3b | US$ 1.4b | US$ 2.7b | US$ 2.1b | US$ -657.0m | US$ 2.2b | US$ 16.3b | US$ 1.2b | US$ 6.7b | US$ 6.5b | US$ 7.8b | US$ 30.5b | US$ 23.7b | - | 21% | 8% | 2.5× | 0.8× | 3.0× | - | - | - | - |
| 2025 | US$ 16.3b | US$ 1.4b | US$ 2.7b | US$ 2.1b | US$ -603.0m | US$ 2.0b | US$ 15.9b | US$ 1.8b | US$ 6.5b | US$ 6.2b | US$ 8.3b | US$ 29.9b | US$ 23.3b | US$ 0.0m | 21% | 8% | 2.5× | 0.8× | 3.2× | 0% | 28.1× | 5.9× | 3.7 |
| 2024 | US$ 15.4b | US$ 1.4b | US$ 2.7b | US$ 2.1b | US$ -602.0m | US$ 1.7b | US$ 14.2b | US$ 1.1b | US$ 6.1b | US$ 5.8b | US$ 7.0b | US$ 26.9b | US$ 20.8b | US$ 0.0m | 23% | 9% | 2.3× | 0.8× | 3.5× | 0% | 25.3× | 5.7× | 2.0 |
| 2023 | US$ 15.0b | US$ 1.4b | US$ 2.1b | US$ 1.5b | US$ -649.0m | US$ 1.4b | US$ 13.9b | US$ 718.0m | US$ 6.1b | US$ 5.6b | US$ 6.5b | US$ 26.7b | US$ 20.6b | US$ 0.0m | 22% | 9% | 2.3× | 0.9× | 3.2× | 0% | 30.9× | 6.9× | 0.5 |